Pandion Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

Rhea-AI Summary

Pandion Therapeutics (Nasdaq: PAND), a biotechnology firm focused on autoimmune disease treatments, has announced that CEO Rahul Kakkar, M.D. will present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 4:00 p.m. ET. The presentation will be available via a live audio webcast on the company’s website, with a replay offered post-event. Pandion's primary product candidate, PT101, is currently undergoing a Phase 1a clinical trial. This candidate aims to expand regulatory T cells without triggering proinflammatory cells, reflecting the company's innovative approach in treating autoimmune conditions.

WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will present at the upcoming Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 4:00 p.m. ET.

A live audio webcast of the presentation will be available in the Investors and News section of Pandion Therapeutics’ website at https://www.pandiontx.com/. A replay of the webcast will be available shortly following the presentation.

About Pandion Therapeutics
Pandion Therapeutics is developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion’s TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform enables the company to create a pipeline of product candidates using immunomodulatory effector modules, with the ability to also combine an effector module with a tissue-targeted tether module in a bifunctional format. Pandion’s lead product candidate PT101, a combination of an interleukin-2 mutein effector module with a protein backbone, is designed to selectively expand regulatory T cells systemically, without activating proinflammatory cells, such as conventional T cells and natural killer cells, is currently in a Phase 1a clinical trial. Pandion is continuing to develop and expand its library of effector and tether modules as part of its earlier-stage research and discovery pipeline. For more information, please visit www.pandiontx.com.

For further information, please contact:

Media:
Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investors:
Michelle Avery
Pandion Therapeutics
857-273-0444
investors@pandiontx.com

FAQ

What is the date and time of Pandion Therapeutics' presentation at the Stifel 2020 Virtual Healthcare Conference?

Pandion Therapeutics will present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 4:00 p.m. ET.

Where can I watch the Pandion Therapeutics presentation online?

You can watch the Pandion Therapeutics presentation live through an audio webcast available in the Investors and News section of their website.

What is the main focus of Pandion Therapeutics' research?

Pandion Therapeutics focuses on developing novel therapeutics to meet the needs of patients with autoimmune diseases.

What is PT101 and what is its purpose?

PT101 is Pandion Therapeutics' lead product candidate, designed to expand regulatory T cells while avoiding the activation of proinflammatory cells, and is currently in a Phase 1a clinical trial.